Tonix sues Dr. Reddy's over generic TONMYA patent challengeNov 13Regulatory decisioncyclobenzaprineTonix Pharmaceuticals, Inc.
Tonix posts $15 million in TONMYA sales for Q3, cites pipeline progressNov 9Quarterly updatecyclobenzaprineTonix Pharmaceuticals, Inc.
Tonix reports preliminary TONMYA revenue of $14.0M to $15.0M for Q3 2026Oct 15Quarterly updatecyclobenzaprineTonix Pharmaceuticals, Inc.
Tonix receives Paragraph IV challenge against TONMYA patents from Dr. Reddy'sOct 2Regulatory decisioncyclobenzaprineTonix Pharmaceuticals, Inc.
Tonix Pharmaceuticals names CEO Seth Lederman as interim chief medical officerAug 18PeopleTonix Pharmaceuticals, Inc.
Tonix reports Q2 2026 results, TONMYA sales rise 197%, HORIZON trial beginsAug 10Quarterly updatecyclobenzaprineTonix Pharmaceuticals, Inc.
Tonix says FDA aligns on Phase 2 design for Lyme antibody TNX-4800Aug 3Regulatory milestoneTonix Pharmaceuticals, Inc.
Yale registers Phase 2 trial of Tonix's TNX-1900 for pituitary surgery painJul 28Trial updateTonix Pharmaceuticals, Inc.
Tonix Pharmaceuticals CMO Gregory Sullivan to retire in August 2026Jul 21PeopleTonix Pharmaceuticals, Inc.
Tonix enrolls first patient in Phase 2 depression trial of TNX-102 SLJun 29Trial updatecyclobenzaprineTonix Pharmaceuticals, Inc.